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A B S T R A C T   
Emerging beta-coronaviruses (β-CoVs), including Severe Acute Respiratory Syndrome CoV-1 (SARS-CoV-1), 
Middle East Respiratory Syndrome-CoV (MERS-CoV), and Severe Acute Respiratory Syndrome CoV-2 (SARS- 
CoV-2, the cause of COVID19) are responsible for acute respiratory illnesses in human. The epidemiological 
features of the SARS, MERS, and new COVID-19 have revealed sex-dependent variations in the infection, fre-
quency, treatment, and fatality rates of these syndromes. Females are likely less susceptible to viral infections, 
perhaps due to their steroid hormone levels, the impact of X-linked genes, and the sex-based immune responses. 
Although mostly inactive, the X chromosome makes the female’s immune system more robust. The extra 
immune-regulatory genes of the X chromosome are associated with lower levels of viral load and decreased 
infection rate. Moreover, a higher titer of the antibodies and their longer blood circulation half-life are involved 
in a more durable immune protection in females. The activation rate of the immune cells and the production of 
TLR7 and IFN are more prominent in females. Although the bi-allelic expression of the immune regulatory genes 
can sometimes lead to autoimmune reactions, the higher titer of TLR7 in females is further associated with a 
stronger anti-viral immune response. Considering these sex-related differences and the similarities between the 
SARS, MERS, and COVID-19, we will discuss them in immune responses against the β-CoVs-associated syn-
dromes. We aim to provide information on sex-based disease susceptibility and response. A better understanding 
of the evasion strategies of pathogens and the host immune responses can provide worthful insights into 
immunotherapy, and vaccine development approaches.   
1. Introduction 
Following the 2002 outbreak of SARS and the 2012 outbreak of 
MERS, COVID-19 is the third 21-century coronavirus-related outbreak 
that has emerged in the human populations and has made the World 
Health Organization (WHO) declare the red level alert [1]. Coronavi-
ruses are a group of pathogenic, large (~30 kb), positive- and single- 
standard RNA viruses with significant effects on animal and human 
health. Most of them may result in respiratory or enteric infections that 
can be serious and life-threatening [2]. Many of the well-known path-
ogenic HCoVs, including SARS-CoV-1, MERS-CoV, and the recently 
identified SARS-CoV-2, are the species of the Betacoronavirus (Beta- 
CoV) genus in the coronavirus family. Beta-CoV members are of a zoo-
notic origin and are associated with a variety of challenging issues such 
as high human-to-human transmission and low clinical manifestation 
rates [3–5]. An epidemiological analysis of SARS, MERS, and COVID-19 
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diseases indicates that the infection and fatality rates of these three vi-
ruses are affected by age and sex distributions in a particular population 
[6]. According to the previous studies, the fatality rates of all the three 
mentioned HCoV-related syndromes are higher in males [7–9]. The 
underlying mechanisms that mediate these sex-based variations are 
complicated and may originate from a variety of sex-dependent genetic, 
epigenetic, and hormonal immunity factors [10]. 
Today, sex is a fundamental biological variable that can affect the 
intrinsic immune defense against pathogenic agents such as bacteria, 
fungi, and viruses. We know that both the innate immune system (which 
has a critical role in the early response against the pathogenic agents) 
and the adaptive immune system (which is involved in the long-lasting 
protection and tissue repair) are affected by sex. Many reports have 
focused on the sex-based differences in immunological pathways acti-
vated during the host-pathogen interactions [11,12]. In this regard, 
males are more sensitive to several infectious agents, including viruses. 
This observation can be related to a relatively weaker immune protec-
tion in this sex type [13,14]. It has been proven that females are more 
protected against viral infections, which can be assigned to both phys-
iological and immunological female-specific responses [14,15]. Never-
theless, the more robust immune response in females is a double-edged 
sword, and in some cases, it can contribute to immune deficiencies and 
autoimmune diseases [10,16,17]. Different production rates and me-
tabolisms of the steroid hormones, the effect of the additional X chro-
mosome on the production rate of some essential genes involved in the 
immune response, and sex-dependent expression of the disease- 
susceptibility genes are the leading causes which make males more 
susceptible and vulnerable to viral infections [3,17]. 
The X-chromosome is sometimes known as the architect of the im-
mune system. Many immune regulatory genes are located on this 
chromosome, and it seems that many X-chromosome-linked miRNAs can 
be substantially involved in the immune system’s various functions. 
However, more shreds of evidence are needed to attribute the sex- 
specific immune responses to the X-linked miRNAs [12,18]. Further, 
physiological differences followed by sex-specific hormone profiles can 
directly or indirectly affect the immune responses. For example, the 
male sex hormone (e.g. testosterone) inhibits the innate immune 
response by decreasing the cytokine, macrophage, and immunoglobulin 
production rates; in contrast, the female sex hormones (e.g. estrogen) 
can either suppress the immune system or strengthen its capacity in a 
dual function at high and low concentrations of the immune modulators, 
respectively [17,19,20]. Until the time of this writing, no effective 
preventive strategy or treatment approach has been introduced for the 
SARS-CoV-1 and MERS-CoV infection but recentlysome clinical phase I 
vaccines have been candidates for the treatment of COVID 19. However, 
more stringent testing for safety, and evaluation of different immuno-
logical responses to these vaccines is required. Hence, having the bulk of 
previous knowledge on the sex-dependent immune responses, in the 
present article, after providing a brief introduction to the three rebel-
lious Beta coronaviruse-associated diseases (i.e. SARS, MERS, and 
COVID-19), we will focus on the sex-dependent immune responses 
against these HCoVs. We hope that the information provided in this 
article can help to give an insight into the immunological features of the 
new and emerging respiratory diseases and offer some clues to alleviate 
the circulation of these viruses. 
2. The Betacoronavirus genus 
According to the molecular taxonomic hierarchy, the four genera of 
the CoVs (i.e. Alpha-CoVs, Beta-CoVs, Gamma-CoVs, and Delta-CoVs) 
are classified in the subfamily of the coronavirinae and the family of 
the coronaviridae. Among these four genera, Alpha- and Beta- CoVs 
mostly infect mammals and humans, while Gamma- and Delta- CoVs 
generally infect birds and fishes. However, some human infections are 
also attributed to some members of these species. The genome of the 
CoVs is a single-stranded positive-sense RNA (+ssRNA) molecule that is 
about 30 kb in length and contains a 5′-cap and 3′-poly-A tail [21]. This 
genome is wrapped in a phosphorylated nucleocapsid protein, which is 
further buried in the viral membrane. The CoVs’ viral membrane of 
CoVs is composed of a phospholipid bilayer, specific spike-glycoprotein 
trimers, glycosylated transmembrane proteins, and envelope proteins 
[22]. The name corona indicates the shape of this family’s particular 
spike-glycoprotein trimer, which exhibits a crown-like structure on the 
virus surface under the electron microscope [23]. 
At least six open reading frames (ORFs) exist in a typical CoV genome 
[24]. A genome-wide analysis of various species of CoVs reveals a fifty- 
four percent sequence identity among their genomes, about fifty-eight 
percent in the nonstructural-protein coding regions, and forty-three 
percent in the structural protein-coding sequences; this means that 
nonstructural proteins are more conserved than the structural protein 
variants among the various species of CoVs. This more considerable 
variation among the structural viral proteins indicates their determinant 
role in adapting the virus species to a new host [25]. 
According to a unique set of ancestry genes, four lineages (A, B, C, 
and D) are commonly recognized in the Beta-CoV genus. SARS-related 
CoV belongs to the B lineage, and MERS-CoV belongs to the C lineage 
[25]. To date, seven HCoV species have been identified, four of which, 
including NL63, HCoV-229E, OC43, and HKU1, mostly trigger mild 
respiratory diseases and three of which, including SARS-CoV-1 and 
MERS-CoV, and the novel SARS-CoV-2, are responsible for the severe 
respiratory syndromes [26]. SARS-CoV-1, MERS-CoV, and SARS-CoV-2 
are known as the Beta-Covs with a zoonotic origin. These three viruses 
have threatened the world with three severe global outbreaks. The first 
one (SARS) was reported in November 2002 in Guangdong China, the 
second (MERS) was first reported in June 2012 in Jeddah, Saudi Arabia, 
and the third (COVID-19) was first reported in December 2019 in 
Wuhan, China [22,27–29]. 
The whole-genome comparison of the newly emerged SARS-CoV-2 
with its counterparts has shown that the SARS-CoV-2 genome has 
~50% similarity with the genome of MERS-CoV and ~70% with SARS- 
CoV-1. Such a comparison reveals possible similarities and differences 
among these three pathogens; it can help a better understanding of any 
possible variations in the relevant responses of their host immune sys-
tems, the host-pathogen interactions, and the mechanisms behind any 
likely anti-immune reactions [29,30]. 
3. The most severe Betacoronavirus-linked syndromes (SARS, 
MERS, and COVID-19) 
SARS, MERS, and COVID-19 are the well-known Beta-CoV-linked 
syndromes, causing severe respiratory deficiencies among human pop-
ulations. Apart from the respiratory system, other tissues, and organs (e. 
g. tonsils and CNS) can be affected during the course of the Beta-CoV- 
linked infections [31]. In the following, some of the essential features 
of these three syndromes will be discussed. Especial attention has been 
given to providing some information about the immunological functions 
of these three diseases. 
3.1. SARS-CoV-1 infection 
The first epidemy of infectious disease (i.e. SARS) was initially re-
ported from Guangdong province, China, at the end of 2002. So far, 
SARS has affected more than 8000 people worldwide [32]. Fever, 
nonproductive cough, myalgia, and dyspnea are mainly mentioned as 
the clinical manifestations of the SARS-CoV-1 infection, which can be 
approved by two primary laboratory diagnostic approaches, i.e. chest 
radiography (to detect air-space opacification in the patients’ lung) and 
molecular tests. A variety of molecular diagnostic tests can be used for 
this purpose, including PCR for detecting the viral genome and enzyme- 
linked immunosorbent assay (ELISA), and immunofluorescence assay 
(IFA) for detecting and tracking of the SARS-CoV-1 specific antibodies 
[33]. Various types of medications can be used to treat SARS-CoV-1 
G. Rahimi et al.                                                                                                                                                                                                                                 
International Immunopharmacology 92 (2021) 107365
3
infection. For example, we can mention Ribavirin (a representer of the 
nucleoside drugs), Lopinavir and Ritonavir (representers of the thera-
peutic protease inhibitors), several interferon therapies, 80R immuno-
globulin G1 (a representer of the therapeutic monoclonal antibodies), 
convalescent plasma, and systemic corticosteroids [34]. 
SARS-CoV-1 (the cause of SARS) is among the coronaviruses that are 
mostly found in bats and transmitted to humans. The ability to choose a 
different host directly results from the CoVs’ high potential for change. 
The large RNA molecule, the high frequency of the genomic recombi-
nation, and the error-prone function of the RNA-dependent RNA poly-
merase (RNA replicas) are mentioned as the primary sources of the 
CoVs’ potential for change [35]. 
Although both SARS-CoV-1 and SARS-CoV-2 belong to the B lineage 
of the Beta-CoV genus, they have different features. For example, the 
nucleocapsid protein of SARS-CoV-1 mostly acts as the antagonist of the 
interferon-gamma (IFN-γ). IFN-γ is a critical cytokine that can directly 
inhibit the viral replication, so its inhibition may result in higher 
infection and hence increased fatality rates in the populations infected 
with SARS-CoV-1. The other differing feature is the different lengths of 
the spike-glycoprotein trimers between these two species. The trimers 
are larger in the SARS-CoV-2 structure; this leads to different receptor- 
binding regions of these two viruses [36,37]. Both SARS-CoVs use 
their spike-glycoprotein trimers to bind to the receptors of their host 
cells. This binding facilitates the entrance of the viral genome into the 
host cell, followed by both the lytic explosion of the cell and stimulation 
of the immune system to fight against the viral infection. The other 
feature of these two SARS-CoVs is their contribution to the elevated 
levels of both IL-6 and IL-8 during the infection cycle. IL-6 is secreted by 
macrophages and T-lymphocytes and IL-8 is secreted by monocytes, 
macrophages, fibroblasts, and keratinocytes during the SARS-CoV in-
fections [34]. 
Numerous studies have reported some sex-specific features of SARS. 
For example, Karlberg et al. investigated any probable relationship be-
tween the case fatality rate and the chronic disease history, age, and sex 
among the Hong Kong population in 2004. According to this research, 
the case fatality rate and hence the disease severity were significantly 
higher among males. A positive correlation was also reported between 
the severity of SARS and chronic disease history and the infection period 
[8]. In another study, Channappanavar et al. examined the sex-based 
susceptibility of mice to the SARS-CoV-1 infection. They discussed the 
three main factors that seemed to be involved in the more robust im-
munity observed in the female mice. They discussed i: the sex-dependent 
level of steroid hormones (unlike estrogen, higher levels of testosterone 
in males can suppress the immune response), ii: the doubled copy 
number of the X-linked immune response genes such as TLR7, which 
plays an essential role in the pathogen recognition and activation of 
innate immunity, and iii: the different conditions of the disease sus-
ceptibility genes in males and females [3]. 
3.2. MERS-CoV infection 
MERS-CoV was formerly known as the human coronavirus EMC/ 
2012 or HCoV-EMC. This virus is the causative agent of MERS. Genomic 
studies have revealed a close phylogenetic relationship between this 
virus and the two bat-specific coronaviruses. This relationship indicates 
the zoonotic origin of this HCoV. The first bat-specific species of these 
coronaviruses was first discovered in Hong Kong in 2007; hence, even 
their non-human variants are relatively new for the researchers. The first 
confirmed case of MERS-CoV in a human was reported in Saudi Arabia in 
2012. During that time, a rapidly progressive contagious pneumonia, 
with a wide range of associated symptoms, was overspreading in this 
country, and the first confirmed case, who died from the pneumonia- 
associated acute renal failure, was a 60-year-old man [38]. 
MERS-CoV causes severe respiratory problems both in the upper and 
lower parts of the respiratory tract. Severe MERS is more prominent in 
people with underlying diseases such as diabetes, hypertension, renal 
diseases, chronic lung diseases, and immunodeficiencies [39]. The 
typical symptoms of MERS-CoV infection include high-grade fever, 
pneumonia, coughing, severe shortness of breath, chest pain, non- 
respiratory symptoms (such as headache, myalgia, and gastrointestinal 
symptoms of nausea, diarrhea, or vomiting), and death. Most of these 
symptoms occur only in severe cases and the older people infected with 
this virus. The most definitive tests for confirming the MERS-CoV 
infection are laboratory cultivation of the virus (sampled from respira-
tory, urine, fecal, or other tissue specimens), serum anti-MERS-CoV 
antibody titers, and chest radiography [38,40]. 
Some studies have shown that the combination of ribavirin (a gua-
nosine analog to hamper RNA synthesis) and IFN-α2b can inhibit MERS- 
CoV infection in vitro [41]. There are also some other reports indicating 
that ribavirin can enhance the anti-viral effects of alisporivir (the in-
hibitor of an immunosuppressant protein, cyclophilin) in laboratory 
experiments [42]. Until now, none of these potential therapeutics (based 
on the conventional and currently-used drugs) have received final 
approval; hence, many researchers have focused on developing new 
therapeutics to fight MERS. An example is the study of Anand et al., in 
which they worked on the structure of the 3C-like protease or 3CLpro 
(an essential protease in the HCoVs replication cycle) to facilitate the 
introduction of the new therapeutic agents [43]. Moreover, when 
necessary, IFNs, a variety of anti-virals, antimicrobials, and antifungal 
agents, can reduce the risk of co-infection during the MERS disease in 
real clinical experiments [44]. Moreover, some latest updates have re-
ported the potential therapeutic effects of the remdesivir and chloro-
quine against SARS, MERS, and COVID-19 [45]. 
Remdesivir (GS-5734) is a nucleotide-based prodrug that is con-
verted to its active form (a ribonucleotide analog) during the meta-
bolism; hence, it is known as an anti-viral agent for a broad spectrum of 
the RNA viruses, including all the Beta-CoV species. This compound was 
first developed to treat hepatitis C, while its beneficial effects were 
further approved for the Ebola virus disease [46,47]. Chloroquine is 
known for its robust antimalarial effects. The potency of chloroquine 
and its derivatives (including phosphate and sulfate salts of chloroquine 
and hydroxychloroquine), as the immune boosters and anti- 
inflammatory agents, is also well established [48,49]. 
In parallel with the efforts to develop new therapeutic products, 
there are also many types of research focusing on developing preventive 
and therapeutic immunization programs. An example is a research by 
Beigel et al., in which a nanostructure MERS-CoV related spike-protein 
was used as a vaccine to immunize transchromosomic cattle and pro-
duce a fully-human polyclonal IgG immunoglobulin (SAB-301) for 
therapeutic purposes [50]. 
MERS-CoV is a large, single-stranded, positive-sense RNA virus that 
consists of over 30,000 nucleotides. The genome of MERS-CoV com-
prises 10 genes and four codes for structural proteins, including the 
specific spike-glycoprotein, the nucleocapsid protein, the virus mem-
brane protein, and the viral envelope. One of the main differences be-
tween the SARS-CoV and the MERS-CoV can be seen in their specific 
spike-glycoproteins. The different receptor-binding domains of these 
viral spike-glycoproteins differentiate the host cells of these viruses. 
Hence, the dipeptidyl peptidase-4 (DPP4) receptor-positive cells are the 
preferred targets of the MERS-CoV. In contrast, the angiotensin- 
converting enzyme 2 (ACE-2) receptor-positive cells are the preferred 
targets of the SARS-CoV. Because DPP4 (also known as CD26) shows a 
more diverse expression pattern on the surface of different cells, MERS- 
CoV has a broader cellular tropism than SARS-CoV [51,52]. 
Several studies have revealed that, in many cases, the risk perception 
of a particular disease is connected with the sex type of infected people. 
Likewise, similar to the other Beta-CoV-associated diseases, MERS-CoV 
infection seems to be more common among males. Moreover, disease 
severity has been proved to be more prominent in patients who are 
suffering from other underlying diseases. An example of these relevant 
studies is published by Sherbini et al. in 2017. In this work, Sherbini 
et al. referred to a report by the WHO and mentioned that 65% of the 
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MERS-CoV confirmed cases during 2012 and July 2015 were males with 
an average age of 50 years [53]. Overall, we can say that males and 
females differ in the severity, prevalence, and pathogenesis of the Beta- 
CoV-related infections, and it is evident that males are more susceptible 
and more vulnerable to these syndromes than females. 
Many researchers worldwide have tried to explain these sex-specific 
variations in both disease susceptibility and vulnerability. For example, 
Klein and Flanagan tried to discuss sex as a determinant biological 
variable that can affect the immune system and hence disease-related 
features and traits. An explanation provided by these authors was the 
higher titer of the activated T helper cells (also known as CD4+ T-cells) 
and higher CD4/CD8 ratios in the females than the males of the same 
age. T helper cells play an essential role in mediating immune responses 
by secretion of specific cytokines, affecting antiviral susceptibility and 
treatment [11]. 
In another relevant study, Alghamdi et al. assessed the epidemio-
logical features of 425 MERS-approved cases in Saudi Arabia in 2014. 
This study also showed more vulnerability of males to MERS-CoV 
infection. Both incidence and death rates were higher in males. They 
proposed that higher testosterone levels and hence elevated 
testosterone-mediated immunosuppression could be involved in their 
observations. They also believed that men spent more time outdoors and 
thus faced a higher risk of exposure to viral agents. Another feature of 
this study was the elucidation of a positive correlation between age and 
the disease rate as well as the impact of the background diseases on the 
MERS-associated death rate. These researchers showed that the disease 
and fatality rates were higher for those aged >45 years. Moreover, they 
showed that young but unhealthy people were also more susceptible and 
vulnerable to MERS-CoV infection. They believed that the weaker im-
mune system in these two groups could explain some features of their 
observations [7]. 
IFN system is a potent weapon of innate immunity which helps fight 
against viral infections. A variety of mechanisms are involved in this 
kind of protection. In one scenario, IFNs are secreted by the infected 
cells and help to inhibit the binding of the viral particles on the neigh-
boring cell surface. Such an IFN immune response is also considered the 
primary response of mammalian cells to viral infections [54,55]. This 
kind of immunity is weaker in MERS-CoV since this virus produces three 
types of IFN antagonist proteins (i.e. ORF4a, ORF4b, and ORF5). These 
three proteins are also involved in the inhibition of the NF-kappaB 
signaling pathways; these pathways are actively involved in the pro-
duction of the cytokines and cell survival requirements [44]. 
3.3. SARS-CoV-2 infection 
On December 31, 2019, an outbreak of a new pneumonia-like syn-
drome in Wuhan was reported to the WHO office in China. Further, this 
new disease (COVID-19) was attributed to a member of a Beta-CoV 
species nominated as SARS-CoV-2. This new disease’s rapid spread 
made the WHO declare a pandemic situation on March 11, 2020 
[56,57]. Some researchers believe that SARS-CoV-2 may have origi-
nated from bats and has been transmitted to humans via an intermediate 
host (e.g. Pangolin) [58]. 
Overall, COVID-19, with approximately 80% asymptomatic or mild 
infection, is not as severe as its two counterparts (MERS and SARS). A 
comparison of the mortality rates of these three acute syndromes (Fig. 1 
a) provides proof for this claim. However, the extremely contagious 
nature of COVID-19 (Fig. 1 b) makes this disease more hazardous [5]. As 
mentioned, an exciting feature of the SARS-CoV-2 is that this viral agent 
can induce extremely variable responses in the exposed individuals. Not 
all the individuals exposed to SARS-CoV-2 will be infected; hence, there 
are a considerable number of COVID-19 asymptomatic carriers, which 
makes many difficulties in the controlling programs. Moreover, not all 
the remaining infected patients will experience severe respiratory 
symptoms, although about 2–6% of the infected people will die from the 
disease’s complications [59]. While more information is still needed to 
describe these observations, there are some explanations for this vari-
able susceptibility and vulnerability in a number of viral infections. An 
example is a study by Dutta et al., in which they showed that different 
major histocompatibility complex (MHC) loci, also known as human 
leukocyte antigen (HLA) haplotypes, might be involved in such variable 
disease manifestations [60]. 
Both the prevalence and severity of COVID-19 seem to be associated 
with the sex of the infected people. For example, the study of Yang et al. 
on 710 patients with the SARS-CoV-2 infection revealed that 67% of 
their sample size were male, and 33% were female [61]. In another 
study by Guan et al., on a population of 1099 COVID-19 patients in 
China, demographic features of the study showed that more share of the 
patients (about 58%) was males as well [62]. One explanation for such 
an observation may be the sex-specific expression of the ACE-2. The 
receptors of ACE-2 are also expressed differently in the sex-specific 
reproductive organs. It has been shown that ACE-2 titer is more prom-
inent in the testis than in ovaries [63]. Zhao et al. applied the single-cell 
sequencing technology to assess the ACE-2 expression levels in the 
healthy human lung tissues. They showed that the ACE-2 expression was 
higher in Asian males than the females of the same ethnicity. As 
mentioned earlier, the ACE-2 receptors are the preferred targets of the 
SARS-CoVs; hence, their higher expression level can be linked with a 
Fig. 1. Basic reproductive number (R0) (a) and Mortality rate (b) of SARS-CoV-2, SARS-CoV, and MERS-CoV. The basic reproductive number of SARS-CoV-2 is still 
contentious. It shows that R0 of COVID-19 is a little higher than SARS and MERS (a), but the COVID-19 mortality rate is lower than SARS and much lower than MERS 
(b) [136]. 
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higher prevalence of the disease [64]. Another important discovery for 
understanding the mechanism of Infection with SARS-CoV-2 involves 
the function of serine protease 2 transmembrane (TMPRSS2), a cell 
surface protein expressed by epithelial cells in different tissues. Coro-
navirus entry and spread in the host is dependent on the TMPRSS2. In 
fact, at first, the viral spike protein is attached to the ACE2, and then, 
viral S protein is trimed by the TMPRSS2 of the host cell to let the 
internalization of viral particles. Understanding the different expression 
levels of the TMPRSS2 in the lungs of males and females can give 
valuable insights into variable infections of coronavirus. Since andro-
gens play a critical role in controlling TMPRSS2, the higher prevalence 
of coronavirus in males can be described by TMPRSS2 [65]. 
Some sex-specific habits may also exacerbate these sex-specific ob-
servations. For example, smoking is more prevalent in men, and it has 
been shown that smoking can be involved in the overexpression of the 
ACE-2 receptors in the lung cells [66]. 
Interestingly, based on its site of expression, ACE-2 can have two 
different functions. This protein can be a transmembrane protein located 
in the specific cell membranes or can be found in plasma. As a trans-
membrane protein, ACE-2 acts as a gateway for SARS-CoV-2 entry, and 
its soluble form acts as an anti-inflammatory agent [67]. 
In general, after exposure to a pathogenic dose of the viral particles, 
SARS-CoV-2 infection occurs in three main steps in patients with severe 
symptoms. In the first step, which is also known as the asymptomatic 
phase of incubation, the virus titer is very low or sometimes unmea-
surable. In the second step, the virus titer is increased and can be 
detected more easily—this higher titer of the virus load is accompanied 
by non-severe symptoms. In the final step, the titer of the virus load is 
exceptionally high, and the patient suffers from severe respiratory 
conditions. During the first two steps of the infection, a specific adaptive 
immune response is needed to prevent the progression of the disease to 
its final malignant stage. In these two steps boosting the immune re-
sponses can be beneficial for the prevention of the disease progression 
[68]. 
The immunology of COVID-19 and hence boosting the immune re-
sponses in this disease in some cases are somehow different from other 
similar respiratory syndromes. For example, a T-cells’ critical function is 
mediating the cytokine release syndrome (CRS), which is often seen in 
severe respiratory malignancies. There are some pieces of evidence 
indicating that T-cells are not sufficiently activated during the SARS- 
CoV-2 infection; alternatively, the unusually high levels of the lym-
phocytes (known as lymphocytosis) during the severe course of the 
COVID-19 indicate that CRS may be mediated via activation of leuko-
cytes in the COVID-19 patients. This insufficient activation of T-cells 
Fig. 2. The life cycles of MERS-CoV, SARS-CoV, and SARS-CoV-2 in host lung cell. The entrance of SARS-CoV and MERS-CoV viruses into cells are happened by an 
endosomal pathway through special receptors on the host cells. The receptor of SARS-CoV is ACE2, which binds through S glycoprotein on the surface of viruses. 
MERS-CoV bind to the DPP4 receptor through S glycoproteins. The viral RNA is released into the cytoplasm after the virus has entered the host cell. Replication of 
genome leads to the production of full-length (− ) RNA copies of the genome as templates for full-length (+) RNA genomes. Also, transcription of the genome leads to 
the production of 7–9 RNAs, which produces some structural proteins. S, M, and E proteins are produced at the endoplasmic reticulum (ER) membrane. Nucleo-
capsids are manufactured in the cytoplasm from genomic RNA and N proteins, followed by budding into the lumen of the intermediate ERGIC (endoplasmic re-
ticulum (ER)–Golgi compartment). The virions are then released by exocytosis from the infected host cell. (life cycle of SARS-CoV-2 is similar to SARS-CoV). The 
artwork is provided by BioRender (https://biorender.com/). 
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during the SARS-CoV-2 infection is associated with the lower levels of 
the IFN-γ than the other similar situations. Accordingly, when using the 
MSC therapy as a boosting strategy to improve the immune responses, it 
would be necessary to pretreat them with IFN-γ; this makes them more 
effective in the promotion of tissue repair or suppression of hyperactive 
immune responses [68–70]. 
4. Pharmacotherapy of the CoV-linked syndromes 
The specific spike-glycoproteins of CoVs, which are essential for their 
entrance into the host cells, are the critical drug targets of any kind (e.g. 
antibodies, small chemicals, or any other inhibitory molecules). We 
know that SARS-CoV infections happen via the attachment of the 
receptor-binding domain of the viral spike-proteins and a specified 
cellular receptor on their host cells (i.e. ACE-2) [23]. In the case of 
MERS, the viral spike-proteins are attached to the dipeptidyl-peptidase 4 
(DPP4), which is also known as CD26. DPP4 is the MERS specific host 
cell receptor, and surprisingly, it does not have any structural similar-
ities with ACE-2 [71,72]. Such a host cell receptor-viral spike-protein 
attachment, followed by the viral particles’ fusion into the host cells, is 
the frontline of the viral infection cycle (Fig. 2) [73,74]. 
Efficacy of a variety repositioned drugs for the CoV-linked syn-
dromes is under investigation. There are several classification for 
COVID-19 drugs, include: nucleotide analogs (remdesivir), nucleoside 
analogs (favipiravir), protease inhibitors (lopinavir/ritonavir.combina-
tion therapy), biologics (tocilizumab and sarilumab), and various types 
of RNA synthesis inhibitors [75,76]. Biomedical therapies including 
varity of immunotherapy approaches are being examined by many re-
searchers worldwide. Some of these efforts consist of inhibiting the 
attachment of the viral particles to their host cells using anti-viral an-
tibodies (either IgM or IgG or both of them) and developing potential 
vaccine products. Data from animal model and humane were assessed by 
vaccine developers and manufactures to develop vaccines against 
COVID-19. There are currently more than 200 developing COVID-19 
vaccines candidates and some of them have developed into clinical 
stages and a few of them have recently moved into final stages of testing 
[77]. Up to Dec. 11, 2020, according to Coronavirus Vaccine Tracker (By 
Carl Zimmer, Jonathan Corum and Sui-Lee Wee), five vaccines have 
introduced for limited use, two vaccines have approved for full use and 
one vaccine (a vaccine from Australia’s University of Queensland) has 
abandoned after trials. These vaccines have been produced base on 
variable types including Inactivated, Non-Replicating Viral Vector, 
Protein Subunit, mRNA and DNA [78]. According to the U.S. Food and 
Drug Administration (FDA), Pfizer-BioNTech COVID-19 Vaccine was the 
first vaccine which has met the statutory criteria for issuance of an EUA. 
this vaccine contains a small piece of the SARS-CoV-2 virus’s mRNA that 
instructs cells in the body to make the virus’s distinctive “spike” protein. 
By receiving this vaccine, body produce copies of the spike protein, 
which does not cause disease, but triggers the immune system to learn to 
react defensively, producing an immune response against SARS-CoV-2 
[79]. Despite the diversity of medical interventions, the fact that inci-
dence of COVID-19, its mortality rate, and the effects of medical in-
terventions vary between males and females, has not substantially 
affected the scientific investigations and very few studies consider 
various therapeutic approaches for the two sexes [80]. Variations in 
weight, body mass index, and hormonal changes (during puberty, 
menstrual cycles, and menopause) can be factors that lead to sexual 
differences in adverse reactions to antiviral drugs [81] Hence, an 
appropriate treatment for patients is the use of hormone therapy. Sex 
hormones such as testosterone, progesterone, and estradiol can be 
considered in these therapeutic processes (Table 1) [80,82,83]. 
5. Sex-dependent immunological responses to viruses 
Sex is among the main determinants that affects both the innate and 
adaptive immune responses. Hence, in many cases, immunological re-
sponses to viruses differ significantly between men and women. These 
sex-based differences are evident in a variety of living organisms. It is 
surprising that, in general, males have a weaker immune system than 
famels. In this regard, many findings have indicated that fatality rate is 
higher in males than age-matched females in all 3 viral infections of 
SARS, MERS, and COVID-19. It should be noted that this higher sus-
ceptibility of males to coronavirus infections increase with advancing 
rise in age [3]. In their study, Ding et al. showed that menstrual status 
and female hormones, including anti-Müllerian hormone (AMH) and 
Estradiol (E2), were associated with the severity of COVID-19 infection. 
Actuallly, nonmenopausal females were milder in the severity and had 
better results than males who were age-matched. This difference 
Table 1 
Summary of clinical studies related to the sex hormone that may be involved in the different response to SARS-CoV-2 between sexes.  
Clinical Trial Study Intervention/ 
Treatment 










Estrogen Therapy in Non-severe 
COVID-19 Patients 
Estrogen Therapy Male ≥ 18 years of age and 





18 Years to 70 
Years (Adult, 
Older Adult) 
March 30, 2021 NCT04539626 
Selective Estrogen Modulation 




Clinical testing positive for 
SARS-Cov-2 by standard RT- 
PCR or equivalent test 
Phase2 390 
participants 






Estrogen Patch for COVID-19 
Symptoms 
Estradiol patch Male ≥ 18 years of age or 
female ≥ 55 years of age 
Phase2 110 
participants 






Phase II RCT to Assess Efficacy of 
Intravenous Administration of 
Oxytocin in Patients Affected by 
COVID-19 (OsCOVID19) 










COVID-19 In-vitro Diagnostic Test 






Males over age 18 who have 
tested positive for SARS- 
CoV-2 infection within the 
University of California 
– 200 
participants 











Males Positive SARS-CoV-2 











Progesterone for the Treatment of 
COVID-19 in Hospitalized Men 
Progesterone 100 
MG 




18 Years and 
older (Adult, 
Older Adult) 
April 17, 2021 NCT04365127  
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disappeared when postmenopausal females were compared with age- 
matched males [84]. 
As the first line of the immune defense, the innate immunity plays a 
critical role in fighting against CoV-related infections. The viruses are 
first sensed through an evolutionarily conserved pathogenic structure/ 
sequence known as the pathogen-associated molecular patterns 
(PAMPs). In the host organism, each specific PAMP of a group of viruses 
is recognized by various germline-encoded pattern recognition receptors 
(PRRs), which induces some relevant immune responses. For example, 
RLRs (the retinoic acid inducible gene 1 (RIG1) like receptors) can 
realize the particular RNA sequence of many RNA viruses, including 
MERS-CoV, SARS-CoVs [85], and Influenza A virus [86]. Upon recog-
nition, the PAMP-TRL (toll like receptors) binding will result in the TRL 
activation and the recruitment of the adapter proteins within the im-
mune cells. The adapter proteins (such as MyD88 and TRIF) can mediate 
a series of protein–protein interactions and signaling pathways within 
the immune cells; hence, they are very important for the immediate 
action of these cells during the viral infections (e.g. the production of the 
interferons, inflammatory factors, cytokines, and chemokines) [87,88]. 
However, SARS-CoV and MERS-CoV were known to escape the host 
recogonition of their dsRNA by replicating in the absent vesicles of 
double membrane PRRs [89]. 
Type-1 IFN secretion is mediated as the result of the PAMP-PRR 
interactions and is among the most critical anti-viral responses. In-
terferons can stimulate the NK cells and macrophages to take part in the 
clearance of the virus particles, on the one hand, or directly involve in 
the IRF anti-viral pathways, on the other hand [90–92]. High expression 
of IRF-7 in females induces the production of IFN-b by dendritic cells 
and can decrease the risk for viral infection adverse outcomes in females 
compared with males [3]. IFN and inflammatory cytokines are higher in 
females than males, which can contribute to more circulation of T cells 
in females [11]. Evidence from studies has revealed that SARS-CoV 
pathogenesis can be controlled by IFN treatment [93]. Like any other 
kind of pathogens, evasion from the innate immune responses can also 
be traced among the CoVs. It has been shown that the Beta-CoVs can 
either control or modify the innate immune responses via several known 
and unknown mechanisms. Some reports have indicated that the SARS- 
and MERS- CoVs are able to inhibit the production of the IFNs. This 
inhibition can lead to limited viral clearance, followed by more severe 
symptoms. Delayed IFN signaling has also been mentioned as a causative 
factor for the high replication number, which occurs during the SARS- 
CoV-2 infection [5,85,94]. In the case of the innate immune system, it 
has been proven that both the titer and activity of the innate immune 
cells (including dendritic cells, monocytes, and macrophages) are higher 
in females (Fig. 3). Moreover, females show more robust inflammatory 
immune responses against pathogenic infections [95]. Observations 
Fig. 3. Sex-specific immune responses to vaccination. Innate and adaptive immune responses to vaccination are overall different in males and females, including sex 
chromosomal and hormonal differences. Sex-based effects of vaccination are more pronounced in females than males. At the first step of immune responses, neu-
trophils and macrophages release more inflammatory cytokines and chemokines in females. Actually, females have more levels of neutrophils and macrophages, but 
in contrast NK cell frequencies are more in males than females. Sex hormones of estrogen mostly influence responses to vaccination. Major histocompatibility 
complex (MHCII) that exists on antigen-presenting cells of dendritic cells, macrophages and B cells, is upregulated by estrogen. Also, while testosterone has an 
inhibitory effect on the expression of TLR7, estrogen exerts a stimulatory impact on them. Also, estrogen leads to more expression of IL-6, IL-8, and monocyte 
chemoattractant protein-1 (MCP-1) in the dendritic cells. In adaptive immunity, estrogen result in antibody glycosylation levels. X-chromosome encodes the genes 
involved in immune responses to vaccination. TLR7 and CD40L locate on the X-chromosome and more expressed in females than males. 
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have indicated that lung intense inflammatory response after SARS 
infection remains even higher in males than in females. In particular, 
males with SARS-CoV infection show high numbers of IMMs, which are 
known as a significant origin of proinflammatory cytokines and che-
mokines in SARS infection [3]. 
Adaptive immune responses are the second line of defense against 
viruses. It has been proven that in the case of viral infections (including 
Beta-CoVs), the function of the Th1 (T helper 1) immune cells is the 
leading adaptive immune response against the viral pathogens [5]. 
During the infection cycles, the cytotoxic T-cells are involved in the 
production of the anti-viral cytokines. They can also kill the infected 
cells [96]. The high rate of genetic variability in the Beta-CoVs and in-
hibition of antigen presentation pathways (which are mediated by MHC 
class 1 and 2), besides many other factors, are responsible for their 
escape from the pre-existing adaptive immune responses [97]. The 
adaptive immune responses are stronger in famales, as well; they elicit 
more robust humoral immune responses and have a higher titer of the 
Th1 cells [95,98]. However, this strength of the immune system makes 
females more susceptible to autoimmune diseases and increased adverse 
biological reactions in vaccination [10,99]. 
Notably, Sex-based differences in both innate and adaptive immune 
responses are among the most determinant factors affecting prophylaxis, 
exposure, pathogenesis, intension, and clearance of the CoVs. Overall, 
famales are less susceptible and less vulnerable to viral infections, 
although, as a result, protective responses upon vaccination programs 
are more severe in females [3,98,100]. There are many biological 
mechanisms underlying all of these different sex-based functions against 
corona viruses. In general, it should be said that sex-based immune re-
sponses can be affected by the individuals’ genetic profile, sex hormone 
expression levels, age, and many environmental variables [11]. In the 
following, we will discuss the main mechanisms involved in all these 
sex-based immunological variations. These pieces of information may be 
beneficial for a better understanding of the success of the therapeutic 
approaches as well as mitigation policies against Beta-Covs. 
5.1. Effects of the sex chromosomes on the host immune responses 
The X chromosome encodes a variety of immune system-related 
genes. The biallelic expression of the X-linked genes dramatically con-
tributes to many immune-based diseases; most of which are the auto-
immune abnormalities. The biallelic expression involves in both 
susceptibility and vulnerability against viral infections, as well [18]. 
Apart from the biallelic expression, we know that the X-linked immune- 
related genes are more active in females than in males [101]. 
Recent studies on the sex-based variability of the innate immune 
system have revealed a different activation pattern for the genes 
involved in the innate immunity between males and females. TLR7, 
TLR8, FOXP3, CD40L (CD154), and the interleukin-1 receptor-associ-
ated kinase 1 (IRAK1) are some examples of these differently activated 
genes. Among these genes, TLR7 and IRAK1 are the key players of the 
pro-inflammatory immune responses [11,12]. TLR7 is among the genes 
which can escape the X-inactivation and hence is overexpressed in fe-
males. The sex-based overexpression of the TLR7 gene is associated with 
a higher expression of the IFNs and the IFN-stimulated genes (ISGs) and 
will ultimately result in higher levels of activation of CD8+ T-cells in 
females [102]. 
It has been proven that females have a diverse cell population with 
preferential expression of either maternal or paternal X-linked genes. 
This phenomenon, which occurs as a result of uneven X-inactivation, is 
known as cellular mosaicism. Cellular mosaicism can lead to reduced 
immune dysregulation (which is associated with a stronger immunity) 
and an increase the number of the wild type gene expression (which is 
followed by increased diversity in the immune responses) in females 
[103–105]. 
In contrast to the Y chromosome, the X chromosome is among the 
most miRNA gene containing chromosomes [11,106]. In addition to the 
immune-related genes, the X chromosome encodes several critical 
microRNAs that can be involved in the regulation of many immune re-
sponses, as well [14,107]. miRNA-18 and miRNA-19, which are encoded 
by X chromosome, have been reported to regulate some immunological 
reactions. Moreover, miR-233 is considered a regulator of neutrophil 
differentiation, and miR-424, miR-503, and miR-542 have been reported 
to downregulate the differentiation of monocytes [11,14]. More con-
centration of miRNAs on the X chromosome can probably result in the 
importance of miRNAs in the sex-based differences in the immune 
system. 
Moreover, the immune system is influenced by age-dependent al-
terations in hormone levels. Studies on SARS-CoV-1, MERS-CoV, and 
SARS-CoV-2 epidemics have revealed that viral infection-linked adverse 
outcomes are lower in younger males and females. There were also more 
infection susceptibility and case fatality rates (CFRs) in older patients 
than in younger patients [108]. This could not be associated with mere 
genetics or chromosomal components and is thought to be related to the 
hormonal effects. The level of sex hormones varies over the life course of 
individuals. Generally, sex steroid levels decrease with a rise in age in 
males and females, which leads to the attenuation of immunity function. 
Estrogen levels in females are low after menopause, which reflects 
weaker immune responses and result in increased susceptibility to viral 
infection in old age [11]. The protective effect of estrogen, which cau-
sees stronger clearance of viruses in females than males, is lost with a 
rise in age, and the immunological advantage dwindles in the aged fe-
males [109]. Considering those findings, administration of hormone 
replacement therapy may assist for treating older cases of SARS-CoVs. 
5.2. Impacts of the sex hormones on the host immunity 
Sex hormones, also known as sex steroids, consist of three main 
classes of hormones, including estrogens, progestogens, and androgens. 
They are responsible for a substantial part of the sex-specific differences. 
All of them can be found in both sex types. The expression levels of the 
androgens are higher in males, while estrogens are more expressed in 
females. Hence, androgens and estrogens are known as the male and 
female sex hormones, respectively. Progesterones are involved in a va-
riety of sex-specific functions in both males and females. The sex-specific 
hormones as well as their sex-specific functions can also affect the im-
mune system of these two sex types and participate in the sex-specific 
immune responses [63,110,111]. Expression of a variety of sex hor-
mone receptors (of any kind) on the surface of the immune cells is a 
proof for this process [14]. 
Estrogens with a dual role in the immune system result in immune 
suppression at a high dose and lead to immune induction at a low dose 
[3,112]. More precisely, in addition to estrogen concentration, there are 
many other factors affecting estrogen activity. Therefore, the effects of 
estrogen can be verified in different cell types and organs and also 
variable conditions in the immune system. Because of the large quantity 
of data about the dual role of estrogen in the immune system, and ac-
cording to the purpose of our study, we focus more on its tendency to 
immunoenhancing. The estrogen-related downstream signaling in fe-
males leads to neutrophil accumulation and also stimulation of adaptive 
immune responses in T-cells [113]. Several studies have revealed that 
estrogens and their receptors (ERα and ERβ) contribute to the regulation 
of immune responses. During IAV (influenza A virus) infection, ERα 
decreases the inflammatory cytokine responses and mortality rate in the 
female mice [113,114]. Likewise, the activation of endothelial estrogen 
receptors has been proven to inhibit the angiotensin II-mediated 
inflammation and ROS generation [115]. ERs were also detected in 
PBMCs and T cell lymphocytes and estrogen could modulate the lym-
phocytes by binding to these specific receptors. It was demonstrated that 
estrogen reduce TNF-α-induced toxicity by inhibition of TNF-α-induced 
signaling in T cells and increase cell survival by apoptosis prevention 
[116]. Generally, via ERS-mediated mechanisms, estrogen modulates 
the Immune activities like inhibition of T suppressor, helping the T 
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helper maturation, induction of CD5 + B cells, production of autoanti-
bodies, and regulation of macrophage activity [112,117]. Recent studies 
have shown that mice treated with estrogen receptor antagonists are 
more susceptible to SARS-COVs. Thus, it can be inferred that estrogen 
may have a protective role against coronaviruse infections [3]. Estrogen 
has also been revealed to alleviate lung myeloperoxidase expression, 
which may happen during extensive inflammation in the coronavirus 
patients [112]. 
As the most potent estrogenic derivative in human, estradiol [118] 
has been reported to elevate innate and adaptive immune responses. 
Estradiol leads to more activation of NK cells and upregulation pro- 
inflammatory cytokines [119]. In a study, estradiol was reported as a 
mitigation agent of coronavirus. The results revealed that estradiol 
might be a candidate as a potetnt drug for controlling coronavirus 
infection by downregulating the ACE-2, a gene that is needed for coro-
navirus cell entry [120]. Moreover, 17β-estradiol was suggested as a 
stimulator of B cell differentiation and antibody secretion by inhibiting 
the activity of suppressor T cells, which suppress the B cells. Estradiol 
can also cause the accumulation of immuneglobin cells (IgM-containing 
and IgM-secreting). However, the high dose of this hormone has been 
shown to be toxic with immunosuppressive effects [112,121]. 
Based on the results of a recent study, the menopausal females had 
more severe COVID-19 infection with increased mortality than the 
nonmenopausal ones. In the above-mentioned experiment, the meno-
pausal patients displayed worse outcomes and higher hospitalization 
proportion than the nonmenopausal patients. These results might be 
associated to estradiol and its related inflammation and immunity 
modulation roles. During a viral infection, estradiol contributes to 
immunopathology by regulating the expression of cytokines and che-
mokines and can help treat the individuals diagnosed with COVID-19 
[122].Testosterone as a male hormone acts differently and leads to the 
inhibition of innate immune responses. Testosterone exerts its immu-
nosuppressive effects by limiting the T- and B-cell proliferation and TLR 
expression [105]. It has also been reported as a potential agent involved 
in the promotion of coronavirus infection [120]. Although testosterone 
generally results in immune suppression and may lead to high suscep-
tibility to virus infection in males, it can exert a protective impact on 
respiratory muscles by its anti-catabolic properties. In light of that, the 
coronavirus patients are substantially damaged in lung and reveal acute 
hypoxemic respiratory failure, testosterone may lead to less assisted 
ventilation in patients [123]. 
Gaskins et al., showed that CRP concentrations is fluctuating during 
menstrual period with a peak on menses. CRP is inversely related with 
levels of endogenous estradiol but positively related with levels of luteal 
progesterone. They provided a comprehensive assay of interplay be-
tween CRP and endogenous hormones in reproductive age woman 
[124]. 
Both estrogen and testosterone have been reported to be associated 
with inflammatory signaling pathways, which are the most theoretical 
accepted pathways involved in corona virus-related damage to the res-
piratory tract. The anti-inflammatory effects of estrogen and testos-
terone have been proved to be useful for therapeutic purposes. Estrogen 
inhibits the pro-inflammatory cytokines, including IL-6, IL-8, and TNFa, 
and causes inflammation suppression in a dose-dependent manner 
[112,124]. Additionally, estrogen restricts the activity of free radicals 
and consequent inflammation because of generation of esterogen- 
induced nitric oxide and regulation of leukocyte recruitment. Notice-
ably, many researches have reported a negative relationship between 
endogenous estrogen and inflammatory hallmarks by investigating the 
anti-inflammatory activities of estrogen, including antioxidant activity, 
antiapoptotic effects on various cell types, and suppression of cytokines 
and the renin-angiotensin system [124,125]. It has also been indicated 
that testosterone has anti-inflammatory effects and can decrees the IL-6 
and TNF-a inflammatory markers [126]. 
The SARS-CoV-2 entry to the cells mediates through ACE2 receptor 
abundantly present on pneumocytes and leads to negative regulation of 
ACE2 which converts Angiotensin (Ang) II to less immune stimulating 
variants of Ang. Ang2 could bind to type 1 Ang receptors that causes 
activation of NF-KB pathway. NF-KB signaling increases cytokine pro-
duction, contraction of the vessels (vasoconstriction), and immune re-
actions. The activated estrogen alpha receptor has been shown to 
prevent the starting of immune responses due to suppression of NF-KB 
signaling [127–129]. Besides as mentioned above, testosterone 
(Androgen) also like estrogen could slap down humoral and cellular 
immune responses where reduces IL-6 and TNF-α by restricting NF-KB 
signaling, similar to estrogen [126].Therefore, both estrogen and 
testosterone as sex hormones could shut down NF-KB signaling as master 
active signaling in COVID-19 disease, can be very promising strategy for 
hormone replacement therapy [123]. 
6. Sex differences in vaccine-induced immunity 
Vaccination is a public health intervention with the greatest impact 
on reducing different diseases and mortality rate and is recognized as a 
cost-benefit public health investment. The first vaccine was used in 1980 
to eradicate smallpox and then poliovirus, Haemophilus influenza type B 
(Hib), etc. [130]. Sexual differences in immune reactions affect both 
innate and acquired immune responses, thereby contributing to varia-
tions in susceptibility to infectious diseases and vaccine responses 
(Fig. 3) [131]. Biological differences related to a person’s sex are the 
principal source of change in the immune response to vaccination. 
Clinical results show that males and females have different reactions to 
viral vaccines in their intrinsic, humoral, and cellular aspects. Sex affects 
the frequency and severity of the harmful side effects of vaccination, 
such as fever, pain, and inflammation [98]. In other words, these 
adverse reactions are more frequent in females. In addition, females 
have higher antibody responses to vaccines than males in equal doses, 
resulting in more inflammatory responses and increased adverse bio-
logical reactions [99]. Different studies have shown a sex disparity in 
vaccination against different viruses such as seasonal influenza virus 
[132], HBV, Hepatitis A, and Herpes simplex-2. All of these studies have 
indicated that both adverse reactions to viruses and post-vaccination 
antibody titers are higher in females than males [98,133,134]. In a 
recent study by Fink et al., males and females were immunized with an 
inactivated H1N1 (a type of influenza) vaccine that primarily caused 
antibody-mediated immunity. After vaccination, females had superior 
antibody responses and demanding defense with an H1N1 drift variant 
than males [135]. In the case of CoVs related disease, vaccines study is 
constantly evolving, but more studies and experiments will be needed to 
exact determination of approval vaccines effects in different sexes. Ac-
cording to sex related variation impact in response to vaccination, 
considering sex based immune studies in vaccine design and production 
will be very helpful and we think that addressing sex-immune profile 
differences can result in more efficient vaccines development. 
7. Conclusion 
With emergence and pandemic spread of new human coronaviruses 
(HCoVs), SARS-CoV-2 (the cause of the COVID-19 disease), which is the 
origin of the serious and occasionally fatal respiratory complaints in 
human, scientists are trying to focus more on different aspects of COVID- 
19 disease to find some strategies to improve the management and 
design specific therapeutic programs. In this regard, the body’s antiviral 
immune fight has great importance. As mentioned previously, the 
antiviral immune responses ear dissimilar between females and males. 
This concept, as the focus of this review, can affect the immunotherapy 
programs and effective vaccine-development against COVID-19. The 
prevalence of Beta-CoV-related infections is usually higher in males. 
Females exhibit more robust innate and adaptive immune responses 
against pathogens, which is associated with lower susceptibility, less 
vulnerability, and faster clearance of the viral particles. However, such a 
strength of the immune system also enhances the immunopathology 
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development. In reaction to viral vaccines, females produce more anti-
body and severe responses than males. The efficiency of anti-viral drugs 
and vaccines in decreasing the viral content and suppressing their effects 
differ between the sexes, and the side effects of these anti-viral drugs and 
vaccines are usually higher in females than males. These different 
immunological responses observed between males and females have 
been attributed to the X chromosome. The human X chromosome en-
codes multiple key genes involved in immune response regulation. 
Further, different activation patterns of some genes like TLR7 in males 
and females lead to the sexual variation of pro-inflammatory responses 
against different pathogens related to the stimulation of cytokins like 
IFNs. Therefore, understanding the sex-related differences in COVID-19 
outbreaks will be a critical tool to recognize the impact of a health 
emergency on individuals and populations and to implement efficient 
strategies, public health interventions, and proper therapies. 
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